Adam Hart

Statistics

Publications

Citations

1.1K

H-Index

Active since

1993

Affiliations

Alexion Pharmaceuticals (United States)(Current)

University of North Carolina at Chapel Hill

International University of Health and Welfare

National Hospital Organization Hanamaki Hospital

Fondazione IRCCS Istituto Neurologico Carlo Besta

Adam Hart is an author at Alexion Pharmaceuticals (United States) specializing in myasthenia gravis, anti-acetylcholine receptor antibodies, and myasthenia gravis pharmacotherapy.

Publications per year

1993–2020

Publications

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Influence of placental malaria infection and maternal hypergammaglobulinaemia on materno-foetal transfer of measles and tetanus antibodies in a rural west African population.

Brown J. Okoko, L H Wesuperuma, Martin O. C. Ota et al. · PubMed · 2001 · 75 citations

Life Sciences, Immunology, Maternal Health +16

Seronegative Myasthenia Gravis: Evidence for Plasma Factor(s) Interfering with Acetylcholine Receptor Functiona

Angela Vincent, Z. Li, Adam Hart et al. · Annals of the New York Academy of Sciences · 1993 · 61 citations

Life Sciences, Immunology, Neurology +11

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

1–5 of 7